Kalorama: After Ebola, Chagas, Dengue Among Next Disease Treats For IVD Industry
NEW YORK, Feb. 11, 2015 /PRNewswire/ -- Kalorama Information thinks that the focus of the nation on a pandemic threat during 2014's Ebola cases presents an opportunity for test makers to develop and market products to combat other infectious disease threats. The IVD market research firm said that Chagas disease, Dengue fever and other diseases have not always received a lot of attention, but could see sales and new products over the next five years. Kalorama Information's ninth comprehensive study of the IVD market was published mid 2014 and the firm plans large studies in next generation sequencing and molecular diagnostics this year.
Kalorama Information's report, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition, is available from Kalorama Information at http://www.kaloramainformation.com/Worldwide-Vitro-Diagnostic-8326563/.
"There is so much emphasis on the burden of HIV, tuberculosis and malaria in developing countries. Many public health and donor-funded initiatives focus on these diseases and fail to tackle other pervasive diseases," said Bruce Carlson, Publisher of Kalorama Information
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major public health burden in Latin America and a potentially serious emerging threat to a number of countries throughout the world. Although public health programs have significantly reduced the prevalence of Chagas disease in Latin America in recent decades, the number of infections in the United States and non-endemic countries in Europe and the Western Pacific Region continues to rise. Moreover, there is still no vaccine or highly effective cure available for the approximately 10 million people currently infected with T. cruzi, a third of which will develop potentially fatal cardiomyopathy and/or severe digestive tract disorders. Responding to concerns about the transmission of Chagas disease through blood, the FDA mandated donor screening in 2007. The AABB Chagas' Disease Biovigilance Network records screening and confirmatory results from the testing of donors for antibodies to Trypanosoma cruzi, the agent of Chagas' disease. As of April 30, 2010, the FDA has approved two blood donor screening tests to screen blood, tissue, and organ donors for the blood-borne parasite T. cruzi – from Abbott Diagnostics and Ortho Clinical Diagnostics. The Network reported that nearly 1,500 donors with Chagas disease have been identified since mandatory donor screening was implemented.
Blood donations in all endemic Latin American countries undergo Chagas screening, and testing is expanding in countries, such as France, Spain and the United States, that have significant or growing populations of immigrants from endemic areas. In Spain, donors are evaluated with a questionnaire to identify individuals at risk of Chagas exposure for screening tests.
Kalorama said that Chikungunya, Dengue, leptospirosis, onchocerciasis (river blindness) are among the diseases that could be focus points for new diagnostic devices. Kalorama Information has been observing trends in the in vitro diagnostic industry for two decades. The firm publishes a biennial comprehensive study of the IVD market, which is now in its ninth edition. Kalorama's The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition is available at http://www.kaloramainformation.com/Worldwide-Vitro-Diagnostic-8326563/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article